Literature DB >> 15661905

Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy.

Chien-Chung Chang1, Michael Campoli, Nicholas P Restifo, Xinhui Wang, Soldano Ferrone.   

Abstract

Scanty information is available about the mechanisms underlying HLA class I Ag abnormalities in malignant cells exposed to strong T cell-mediated selective pressure. In this study, we have characterized the molecular defects underlying HLA class I Ag loss in five melanoma cell lines derived from recurrent metastases following initial clinical responses to T cell-based immunotherapy. Point mutations in the translation initiation codon (ATG-->ATA) and in codon 31 (TCA-->TGA) of the beta(2)-microglobulin (beta(2)m) gene were identified in the melanoma cell lines 1074MEL and 1174MEL, respectively. A hot-spot CT dinucleotide deletion within codon 13-15 was found in the melanoma cell lines 1106MEL, 1180MEL, and 1259MEL. Reconstitution of beta(2)m expression restored HLA class I Ag expression in the five melanoma cell lines; however, the HLA-A and HLA-B,-C gene products were differentially expressed by 1074MEL, 1106MEL, and 1259MEL cells. In addition, in 1259MEL cells, the Ag-processing machinery components calnexin, calreticulin, and low m.w. polypeptide 10 are down-regulated, and HLA-A2 Ags are selectively lost because of a single cytosine deletion in the HLA-A2 gene exon 4. Our results in conjunction with those in the literature suggest the emergence of a preferential beta(2)m gene mutation in melanoma cells following strong T cell-mediated immune selection. Furthermore, the presence of multiple HLA class I Ag defects within a tumor cell population may reflect the accumulation of multiple escape mechanisms developed by melanoma cells to avoid distinct sequential T cell-mediated selective events.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15661905      PMCID: PMC2245899          DOI: 10.4049/jimmunol.174.3.1462

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  44 in total

Review 1.  In search of the 'missing self': MHC molecules and NK cell recognition.

Authors:  H G Ljunggren; K Kärre
Journal:  Immunol Today       Date:  1990-07

2.  A class I antigen, HLA-G, expressed in human trophoblasts.

Authors:  S Kovats; E K Main; C Librach; M Stubblebine; S J Fisher; R DeMars
Journal:  Science       Date:  1990-04-13       Impact factor: 47.728

3.  HLA class I nucleotide sequences, 1995.

Authors:  K L Arnett; P Parham
Journal:  Tissue Antigens       Date:  1995-09

4.  Syngeneic antiidiotypic monoclonal antibodies to the murine anti-HLA-DR,DP monoclonal antibody CR11-462.

Authors:  F Perosa; S Ferrone
Journal:  Hum Immunol       Date:  1988-12       Impact factor: 2.850

5.  Beta 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors.

Authors:  D C Bicknell; A Rowan; W F Bodmer
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

6.  Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA.

Authors:  Z Wang; Y Cao; A P Albino; R A Zeff; A Houghton; S Ferrone
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

7.  Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression.

Authors:  C M D'Urso; Z G Wang; Y Cao; R Tatake; R A Zeff; S Ferrone
Journal:  J Clin Invest       Date:  1991-01       Impact factor: 14.808

8.  Beta 2-microglobulin gene is mutated in a human colon cancer cell line (HCT) deficient in the expression of HLA class I antigens on the cell surface.

Authors:  S Gattoni-Celli; K Kirsch; R Timpane; K J Isselbacher
Journal:  Cancer Res       Date:  1992-03-01       Impact factor: 12.701

9.  Human high molecular weight melanoma-associated antigen mimicry by mouse antiidiotypic monoclonal antibody MK2-23. Characterization of the immunogenicity in syngeneic hosts.

Authors:  Z J Chen; H Yang; S Ferrone
Journal:  J Immunol       Date:  1991-08-01       Impact factor: 5.422

10.  By-passing immunization. Human antibodies from V-gene libraries displayed on phage.

Authors:  J D Marks; H R Hoogenboom; T P Bonnert; J McCafferty; A D Griffiths; G Winter
Journal:  J Mol Biol       Date:  1991-12-05       Impact factor: 5.469

View more
  32 in total

1.  High numbers of PDCD1 (PD-1)-positive T cells and B2M mutations in microsatellite-unstable colorectal cancer.

Authors:  Jonas Janikovits; Meike Müller; Julia Krzykalla; Sandrina Körner; Fabian Echterdiek; Bernd Lahrmann; Niels Grabe; Martin Schneider; Axel Benner; Magnus von Knebel Doeberitz; Matthias Kloor
Journal:  Oncoimmunology       Date:  2017-11-06       Impact factor: 8.110

2.  Mechanisms of malignant glioma immune resistance and sources of immunosuppression.

Authors:  German G Gomez; Carol A Kruse
Journal:  Gene Ther Mol Biol       Date:  2006

Review 3.  Immunotherapy for prostate cancer: biology and therapeutic approaches.

Authors:  Edward Cha; Lawrence Fong
Journal:  J Clin Oncol       Date:  2011-08-08       Impact factor: 44.544

4.  Deciphering the genetic evolution of T-cell resistance in melanoma.

Authors:  Antje Sucker; Annette Paschen
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

5.  STING Signaling in Melanoma Cells Shapes Antigenicity and Can Promote Antitumor T-cell Activity.

Authors:  Rana Falahat; Patricio Perez-Villarroel; Adam W Mailloux; Genyuan Zhu; Shari Pilon-Thomas; Glen N Barber; James J Mulé
Journal:  Cancer Immunol Res       Date:  2019-08-28       Impact factor: 11.151

Review 6.  Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack.

Authors:  Fade Mahmoud; Bradley Shields; Issam Makhoul; Nathan Avaritt; Henry K Wong; Laura F Hutchins; Sara Shalin; Alan J Tackett
Journal:  Cancer Biol Ther       Date:  2017-05-17       Impact factor: 4.742

7.  Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy.

Authors:  Chien-Chung Chang; Giuseppe Pirozzi; Shao-Hsuan Wen; I-Hsin Chung; Bau-Lin Chiu; Simona Errico; Monica Luongo; Maria Luisa Lombardi; Soldano Ferrone
Journal:  J Biol Chem       Date:  2015-09-17       Impact factor: 5.157

8.  Synthesis of beta(2)-microglobulin-free, disulphide-linked HLA-G5 homodimers in human placental villous cytotrophoblast cells.

Authors:  Pedro J Morales; Judith L Pace; Jeralyn Sue Platt; Daudi K Langat; Joan S Hunt
Journal:  Immunology       Date:  2007-05-02       Impact factor: 7.397

9.  Antiangiogenesis immunotherapy induces epitope spreading to Her-2/neu resulting in breast tumor immunoediting.

Authors:  Matthew M Seavey; Yvonne Paterson
Journal:  Breast Cancer (Dove Med Press)       Date:  2009-10-05

10.  Total HLA class I loss in a sarcomatoid renal carcinoma cell line caused by the coexistence of distinct mutations in the two encoding beta2-microglobulin genes.

Authors:  Chin-Hsuan Hsieh; Ya-Jan Hsu; Chien-Chung Chang; Hsin-Chun Liu; Kun-Lung Chuang; Cheng-Keng Chuang; See-Tong Pang; Kenichiro Hasumi; Soldano Ferrone; Shuen-Kuei Liao
Journal:  Cancer Immunol Immunother       Date:  2008-08-15       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.